

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
30 August 2018 (30.08.2018)



(10) International Publication Number
WO 2018/156741 A1

(51) International Patent Classification:

C07K 16/40 (2006.01) **A61K 47/18** (2017.01)
A61K 39/395 (2006.01)

(21) International Application Number:

PCT/US2018/019189

(22) International Filing Date:

22 February 2018 (22.02.2018)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/462,266 22 February 2017 (22.02.2017) US

(71) Applicant: **AMGEN INC.** [US/US]; One Amgen Center Drive, Thousand Oaks, California 91320-1799 (US).

(72) Inventors: **SLOEY, Christopher James**; 474 Calle Veracruz, Newbury Park, California 91320 (US). **KANAPURAM, Sekhar**; 5675 Via Bonita, Thousand Oaks, California 91320 (US). **CUI, Huanchun**; St. Jakobstrasse 68, 4147 Aesch, Basel Land (CH). **CHAN, Chio Mui**; 1180 NE 63rd Way, Unit 1010, Hillsboro, Oregon 97124 (US). **BINABAJI, Elahch**; 11734 Wilshire Blvd., Apt. C1501, Los Angeles, California 90025 (US).

(74) Agent: **ZINKL, Gregory M.**; One Amgen Center Drive, Thousand Oaks, California 91320-1799 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

Published:

— with international search report (Art. 21(3))
— with amended claims (Art. 19(1))
— with sequence listing part of description (Rule 5.2(a))



WO 2018/156741 A1

(54) Title: LOW-VISCOSITY, HIGH-CONCENTRATION EVOLOCUMAB FORMULATIONS AND METHODS OF MAKING THE SAME

(57) Abstract: Provided herein are formulations of PCSK9-binding polypeptides, such as those comprising evolocumab, that comprise N-acetyl arginine and have reduced viscosities when compared to formulations lacking N-acetyl arginine. Provided herein are also methods of formulating such compositions that are advantageous in that they conserve certain components. Such formulations comprising PCSK9-binding polypeptides can be administered to patients to treat and/or prevent PCSK9-related diseases, conditions, and disorders.